Kinnate Biopharma Inc - Company Profile
Powered by 
All the data and insights you need on Kinnate Biopharma Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Kinnate Biopharma Inc Strategy Report
- Understand Kinnate Biopharma Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Kinnate Biopharma Inc (Kinnate Biopharma) is a biotechnology company that develops the small molecule kinase inhibitor candidates for difficult-to-treat, cancers associated with genetic alterations. It advancing the development of its lead-targeted therapy FGFR and RAF candidates. The company also provide BRAF protein and biomarker-driven approach to drive the preclinical and clinical development of its translational research programs. Kinnate Biopharma also carries out small molecule development programs, such as Cyclin-Dependent Kinase 12 (CDK12) inhibitor in KIN004 program for the treatment of ovarian carcinoma (OC), triple-negative breast cancer (TNBC) and metastatic castration-resistant prostate cancer (mCRPC). It has operations in San Francisco, the US. Kinnate Biopharma is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
11975 El Camino Real, Ste 101, Suite 101, San Diego, California, 92130
Website
www.kinnate.com
Telephone
1 858 2994699
No of Employees
27
Industry
Pharmaceuticals and Healthcare
Kinnate Biopharma Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline: |
| FGFR Candidates |
| Exarafenib Candidates |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In March, the company entered into an agreement to sell its investigational pan-RAF inhibitor, exarafenib, and other pan-RAF program assets to Pierre Fabre Medicament, SAS. |
| 2023 | New Products/Services | In April, the company announced the addition of two new internally developed next generation development candidates to its targeted oncology pipeline, a brain penetrant mitogen-activated protein kinase (MEK) inhibitor and a highly selective mesenchymal-epithelial transition factor gene (c-MET) inhibitor. |
| 2023 | Acquisitions/Mergers/Takeovers | In February, the company acquired ownership stake in Kinnjiu Biopharma Inc. |
Competitor Comparison
| Key Parameters | Kinnate Biopharma Inc | F. Hoffmann-La Roche Ltd | Pfizer Inc | Novartis AG | Hanmi Pharmaceuticals Co Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | Switzerland | South Korea |
| City | San Diego | Basel | New York | Basel | Hwaseong |
| State/Province | California | - | New York | - | Seoul |
| No. of Employees | 27 | 103,605 | 88,000 | 76,057 | 2,095 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Dean J. Mitchell | Chairman | Executive Board | 2020 | 67 |
| Nima Farzan | Director; Chief Executive Officer | Executive Board | 2020 | 47 |
| Neha Krishnamohan | Executive Vice President - Corporate Development; Chief Financial Officer | Senior Management | 2021 | 36 |
| Mark Meltz | Chief Operating Officer; General Counsel | Senior Management | 2020 | 49 |
| Richard Williams | Chief Medical Officer | Senior Management | 2020 | 54 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer